Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MLAB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure of CEO (new) — Current CEO Gary Owens is departing, though the company states this is not due to any disagreement.
Mesa Labs CEO Gary Owens departing April 13; Dr. Siddhartha Kadia named successor
Filed March 9, 2026 · Period ending March 3, 2026 · ~1 min read
Key Changes
-
high
Current CEO Gary Owens will depart April 13, 2026, after a board-initiated leadership transition. The company states the separation is not due to any disagreement on operations, policies, or practices.
Item 5.02 verify on EDGAR → -
high
Dr. Siddhartha Kadia (age 56) appointed new President and CEO effective April 13, 2026, following a comprehensive external search. He brings 20+ years in life sciences and diagnostics, most recently as CEO of Calibre Scientific.
Item 5.02 verify on EDGAR → -
medium
Dr. Kadia's compensation includes $850K base salary, 100%+ annual bonus opportunity (minimum $850K), and $6M in equity awards ($3M RSUs vesting over 3 years, $3M PSUs with 0-200% payout based on performance).
Item 5.02 verify on EDGAR → -
low
Dr. Kadia will also join Mesa's Board of Directors effective April 13, 2026, giving him dual CEO and board governance roles.
Item 5.02 verify on EDGAR →
Summary
Mesa Laboratories is executing a planned CEO transition, with Gary Owens departing April 13, 2026, and Dr. Siddhartha Kadia taking over the same day. The board emphasizes this was part of a deliberate succession process with an external search, not a crisis departure—Owens' exit involves no disclosed disagreements. Dr.
Kadia's background in life sciences and diagnostics aligns with Mesa's business, and his recent role as CEO of Calibre Scientific suggests relevant operating experience. For retail holders, leadership changes always carry execution risk, especially at smaller companies like Mesa Labs.
The $6 million equity package with three-year vesting and performance hurdles suggests the board is focused on retention and alignment with long-term results. Watch for Dr. Kadia's first earnings call and any strategic shifts he announces—new CEOs often bring fresh priorities that can reshape near-term operations. The separation terms for Owens are still being finalized, so a follow-up filing may clarify any severance costs.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On March 3, 2026, Mesa Laboratories, Inc. (“Mesa” or the “Company”) initiated a leadership transition pursuant to which Gary Owens will depart as President and Chief Executive Officer of the Company, effective on or about April 13, 2026 (the “Transition Date”). Mr. Owens' separation from the Company is not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
Gary Owens is leaving his role as President and CEO effective around April 13, 2026. The company explicitly states this departure is not due to any disagreement about operations, policies, or practices. The separation terms are still being finalized.
Added in current filing · verify on EDGAR →
Upon the commencement of his employment, Dr. Kadia will be entitled to an equity award consisting of restricted stock units (“RSUs”) with an estimated value of $3.0 million and performance share units (“PSUs”) with an estimated target value of $3.0 million, each to be granted at the times and to cover a target number of shares as set forth in the Employment Agreement. The RSUs shall vest and be earned in equal 1/3rd increments on the first three anniversaries of their grant date, contingent on Dr. Kadia’s continued employment through each anniversary date. The PSUs shall have a potential payout between 0% and 200% of the target number of shares based on achievement of one or more metrics determined by the Compensation Committee, and will vest and be earned contingent on Dr. Kadia’s continued employment through the third anniversary of their grant date.
Dr. Kadia will receive $3.0 million in RSUs vesting equally over three years and $3.0 million in PSUs with potential payout ranging from 0% to 200% based on performance metrics, also vesting after three years. This $6 million equity package aligns his interests with long-term shareholder value and retention.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
The Board has also approved the appointment of Dr. Kadia as a member of the Board, effective as of the Effective Date.
Dr. Kadia will join Mesa's Board of Directors effective April 13, 2026, in addition to his CEO role. This dual appointment is common for CEOs and gives him direct board-level governance authority.
Event · Item 7.01 — Regulation FD Disclosure
Mesa Labs issued a news release on March 9, 2026 under Regulation FD; no material details disclosed in the 8-K body itself.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
On March 9, 2026, the Company issued a news release announcing the foregoing updates. A copy of the news release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Mesa Labs disclosed that it issued a news release on March 9, 2026, with the content provided in Exhibit 99.1. The 8-K body does not specify what the updates are, only that they were announced publicly. This is a procedural Regulation FD filing to ensure fair disclosure of material information.
Event · Item 9.01 — Financial Statements and Exhibits
Mesa Labs entered into an employment agreement with Siddhartha Kadia on March 3, 2026.
Added in current filing · verify on EDGAR →
Employment Agreement, dated as of March 3, 2026, by and among Mesa Laboratories, Inc. and Siddhartha Kadia
Mesa Laboratories entered into an employment agreement with Siddhartha Kadia effective March 3, 2026.1. A news release dated March 9, 2026 is also attached as Exhibit 99.1, which may contain additional details.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 5, 2026 · How we verify